Published in

Elsevier, Clinical Oncology, 10(28), p. 666-667, 2016

DOI: 10.1016/j.clon.2016.07.004

Links

Tools

Export citation

Search in Google Scholar

Response to 'High Risk of Neutropenia for Hormone-naive Prostate Cancer Patients Receiving STAMPEDE-style Upfront Docetaxel Chemotherapy in Usual Clinical Practice', by Tanguay et al.

Journal article published in 2016 by Nd D. James, Mr R. Sydes ORCID, Noel W. Clarke, Mkb K. B. Parmar, Aswr W. S. Ritchie
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Madam — Tanguay and colleagues presented data on patients treated with docetaxel [1]. We agree that the reported rates of neutropenia-based toxicities vary across the trials, as do the categories against which toxicities are reported.